The non-langerhans histiocytoses, a nosologic category to which juvenile xa
nthogranuoma (JXG) belongs. represent a heterogenous collection of disorder
s related to the monocyte/macrophage lineage. The dermal dendrocyte was pre
viously proposed as the cell of origin for JXG on the basis of Factor XIIIa
reactivity, a suggestion that does not fully explain the occasional xantho
granulomatous proliferations localizing exclusively to extracutaneous sites
. This study applies a panel of recently developed immunohistochemical mark
ers to JXGs and relates the phenotype: of tills process to new concepts of
monocyte/dendritic cell ontopeny. Twenty-seven JXG, ten dermatofibromas IDF
), and ten age-matched normal skin specimens were stained using standard im
munohistochemistry methods, and all JXGs were fascin+ and CD68+, although 2
6 of 27 were reactive for HLA-DR, 25 of 27 for Factor,XIIIa, 25 of 27 for L
CA: 21 of 27 for CD4, and 8 of 27 for polyclonal s100. Six of those eight p
olyclonal S100+ cases wire also reactive for monoclonal S100. None of those
cases was reactive for CD1a, CU3, CD21, CD31. of CD35. Eight of ten dermat
ofibromas were FXIIIa+: all were negative for HLA-DR, LCA, CD4, and polyclo
nal s100. In controls, fascin+ dendritic cells were present hut did not sta
in for Factor XIIIa, S100, or CD I. Based on the morphologic and phenotypic
overlap of the lesional cells in JXGs and plasmacytoid monocytes, it would
appear that the plasmacytoid monocyte might de considered the putative nor
mal counterpart of;he major cellular population of JXGs, a proposal that he
lps explain the extra-cutaneous, visceral. and soft tissue location that ha
ve been reported for occasional cases of JXG. We would also conclude that n
either Factor XIIIa- nor S100+ results should preclude the diagnosis of JXG
, and find that reactivity for CD4 and LCA may be used to distinguish JXG f
rom DF when the latter is heavily lipidized or the former. is not.